With mid-stage data on its lead drug for tardive dyskinesia--a chronic movement disorder--expected in early 2015, Waltham, MA-based Synchroneuron says it's raised $20 million from its sole investor: Morningside Technology. The biotech is also planning to launch studies for SNC-102 in Tourette syndrome and post-traumatic stress syndrome. Accellient seeded Synchroneuron up to its $6 million Series A from Morningside. Release